Colorectal cancer in Crohn’s colitis is comparable to sporadic colorectal cancer

International Journal of Colorectal Disease

Volumn 31, Issue 5, 2016, Pages 973-982

  Lennerz, Jochen K ^a   van der Sloot, Kimberley W J ^a   Le, Long Phi ^a   Batten, Julie M ^a   Han, Jae Young ^a,b   Fan, Kenneth C ^a   Siegel, Corey A ^c   Srivastava, Amitabh ^d   Park, Do Youn ^e   Chen, Jey Hsin ^f   Sands, Bruce E ^g   Korzenik, Joshua R ^d   Odze, Robert D ^d   Dias Santagata, Dora ^a   Borger, Darrell R ^a   Khalili, Hamed ^a   Iafrate, A John ^a   Lauwers, Gregory Y ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Pusan National University School of Medicine   (South Korea)

^f SWEDISH MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Crohn s colitis; SNaPshot; Targeted re sequencing

Indexed keywords

B RAF KINASE; IMMUNOSUPPRESSIVE AGENT; K RAS PROTEIN; MESALAZINE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MICROSATELLITE DNA; MLH1 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1; NRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COLITIS; COLORECTAL CANCER; CROHN DISEASE; DISEASE COURSE; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LYMPH NODE METASTASIS; MALE; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; STEROID THERAPY; TUMOR VOLUME; WILD TYPE; COLORECTAL TUMOR; COMPARATIVE STUDY; COMPLICATION; DNA METHYLATION; FOLLOW UP; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROMOTER REGION; SURVIVAL ANALYSIS;

ADULT; AGED; COLORECTAL NEOPLASMS; CROHN DISEASE; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOPHENOTYPING; MALE; MEMBRANE PROTEINS; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; MUTL PROTEIN HOMOLOG 1; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL ANALYSIS;

EID: 84962313297     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-016-2574-x     Document Type: Article

References (42)

1. Hamilton SR (1985) Colorectal carcinoma in patients with Crohn’s disease. Gastroenterology 89(2):398–407
2. Siegel CA, Sands BE (2006) Risk factors for colorectal cancer in Crohn’s colitis: a case-control study. Inflamm Bowel Dis 12(6):491–496
3. Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF (1973) Crohn’s disease and cancer. N Engl J Med 289(21):1099–1103
4. Castano-Milla C, Chaparro M, Gisbert JP (2014) Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 39(7):645–659. doi:10.1111/apt.12651
5. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143(2):375–381. doi:10.1053/j.gastro.2012.04.016, e371; quiz e313-374
6. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626–1634. doi:10.1200/JCO.2007.14.7116
7. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705–5712. doi:10.1200/JCO.2008.18.0786
8. Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50(1):113–130. doi:10.1111/j.1365-2559.2006.02549.x
9. Sigel JE, Petras RE, Lashner BA, Fazio VW, Goldblum JR (1999) Intestinal adenocarcinoma in Crohn’s disease: a report of 30 cases with a focus on coexisting dysplasia. Am J Surg Pathol 23(6):651–655
10. Svrcek M, Cosnes J, Beaugerie L, Parc R, Bennis M, Tiret E, Flejou JF (2007) Colorectal neoplasia in Crohn’s colitis: a retrospective comparative study with ulcerative colitis. Histopathology 50(5):574–583. doi:10.1111/j.1365-2559.2007.02663.x
11. Sjoqvist U, Befrits R, Soderlund S, Ost A, Karlen P, Tribukait B, Rubio C, Rutgeerts P, Geboes K, Lofberg R (2005) Colorectal cancer in colonic Crohn’s disease—high frequency of DNA-aneuploidy. Anticancer Res 25(6C):4393–4397
12. Liu X, Goldblum JR, Zhao Z, Landau M, Heald B, Pai R, Lin J (2012) Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and Lynch syndrome-related colorectal adenocarcinoma. Am J Surg Pathol 36(8):1228–1233. doi:10.1097/PAS.0b013e318253645a
13. Kamiya T, Ando T, Ishiguro K, Maeda O, Watanabe O, Hibi S, Mimura S, Ujihara M, Hirayama Y, Nakamura M, Miyahara R, Ohmiya N, Goto H (2012) Intestinal cancers occurring in patients with Crohn’s disease. J Gastroenterol Hepatol 27(Suppl 3):103–107. doi:10.1111/j.1440-1746.2012.07082.x
14. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5A–36A
15. AJCC (2010) Cancer staging manual, 7th edn. Springer, New York
16. Aaltonen LA, Hamilton SR, World Health Organization., International Agency for Research on Cancer. (2000) Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours. IARC Press; Oxford University Press (distributor, Lyon Oxford)
17. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2(5):146–158. doi:10.1002/emmm.201000070
18. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257
19. Pino MS, Mino-Kenudson M, Wildemore BM, Ganguly A, Batten J, Sperduti I, Iafrate AJ, Chung DC (2009) Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J Mol Diagn 11(3):238–247. doi:10.2353/jmoldx.2009.080142
20. Park do Y, Srivastava A, Kim GH, Mino-Kenudson M, Deshpande V, Zukerberg LR, Song GA, Lauwers GY (2009) CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. Mod Pathol 23(1):54–61. doi:10.1038/modpathol.2009.135
21. Park do Y, Srivastava A, Kim GH, Mino-Kenudson M, Deshpande V, Zukerberg LR, Song GA, Lauwers GY (2008) Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia. Am J Surg Pathol 32(4):524–533. doi:10.1097/PAS.0b013e31815b890e
22. Harlan LC, Hankey BF (2003) The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 21(12):2232–2233. doi:10.1200/JCO.2003.94.023
23. Aust DE, Haase M, Dobryden L, Markwarth A, Lohrs U, Wittekind C, Baretton GB, Tannapfel A (2005) Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int J Cancer 115(5):673–677. doi:10.1002/ijc.20925
24. Eaden J (2004) Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 20(Suppl 4):24–30. doi:10.1111/j.1365-2036.2004.02046.x
25. Ribeiro MB, Greenstein AJ, Sachar DB, Barth J, Balasubramanian S, Harpaz N, Heimann TM, Aufses AH Jr (1996) Colorectal adenocarcinoma in Crohn’s disease. Ann Surg 223(2):186–193
26. Canavan C, Abrams KR, Mayberry J (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 23(8):1097–1104. doi:10.1111/j.1365-2036.2006.02854.x
27. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A (2002) Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13(9):1438–1446
28. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ (2005) The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54(9):1283–1286. doi:10.1136/gut.2005.066514
29. Cook MG, Goligher JC (1975) Carcinoma and epithelial dysplasia complicating ulcerative colitis. Gastroenterology 68(5 Pt 1):1127–1136
30. Averboukh F, Ziv Y, Kariv Y, Zmora O, Dotan I, Klausner JM, Rabau M, Tulchinsky H (2011) Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn’s and ulcerative colitis. Color Dis 13(11):1230–1235. doi:10.1111/j.1463-1318.2011.02639.x
31. Hinton JM (1966) Risk of malignant change in ulcerative colitis. Gut 7(5):427–432
32. Slaney G, Brooke BN (1959) Cancer in ulcerative colitis. Lancet 2(7105):694–698
33. Kocer B, Soran A, Erdogan S, Karabeyoglu M, Yildirim O, Eroglu A, Bozkurt B, Cengiz O (2002) Expression of MUC5AC in colorectal carcinoma and relationship with prognosis. Pathol Int 52(7):470–477
34. Nakae K, Mitomi H, Saito T, Takahashi M, Morimoto T, Hidaka Y, Sakamoto N, Yao T, Watanabe S (2012) MUC5AC/beta-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors. World J Gastroenterol 18(39):5551–5559. doi:10.3748/wjg.v18.i39.5551
35. Luka J, Arlen PM, Bristol A (2011) Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC. J Biomed Biotechnol. doi:10.1155/2011/934757.934757
36. Redston M (2009) Chapter 23. Epithelial neoplasms of the large intestine. In: Odze RD, Goldblum JR (eds) Surgical pathology of the GI tract, liver, biliary tract and pancreas. Saunders Elsevier, Philadelphia, pp 597–637
37. Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH (2010) Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn’s and ulcerative colitis based on three decades of experience. Ann Surg. doi:10.1097/SLA.0b013e3181e61e69
38. Greenstein AJ, Sachar DB, Pucillo A, Vassiliades G, Smith H, Kreel I, Geller SA, Janowitz HD, Aufses AH Jr (1979) Cancer in universal and left-sided ulcerative colitis: clinical and pathologic features. Mt Sinai J Med 46(1):25–32
39. Hughes RG, Hall TJ, Block GE, Levin B, Moossa AR (1978) The prognosis of carcinoma of the colon and rectum complicating ulcerative colitis. Surg Gynecol Obstet 146(1):46–48
40. Mortensen N (2011) Commentary on Averbouhk et al. Color Dis 13(11):1235–1236. doi:10.1111/j.1463-1318.2011.02789.x
41. Basseri RJ, Basseri B, Vassilaki ME, Melmed GY, Ippoliti A, Vasiliauskas EA, Fleshner PR, Lechago J, Hu B, Berel D, Targan SR, Papadakis KA (2012) Colorectal cancer screening and surveillance in Crohn’s colitis. J Crohns Colitis 6(8):824–829. doi:10.1016/j.crohns.2012.01.005
42. Farraye FA, Odze RD, Eaden J, Itzkowitz SH (2009) AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138(2):746–774. doi:10.1053/j.gastro.2009.12.035, 774 e741-744; quiz e712-743